ZTS

Zoetis Inc. operates within the Healthcare sector, classified specifically under Drug Manufacturers – Specialty & Generic. It is primarily a global animal health company focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. Its products cover eight core species: dogs, cats and horses in the companion-animal category, and cattle, swine, poultry, fish and sheep in the livestock category.

The revenue mix in 2025 illustrates where the business actually earns money. Companion animal products represented approximately 70% of total revenue, while livestock products represented roughly 29%. U.S. revenue was $5,097 million, or 54% of the total, and International revenue was $4,254 million, or 45%. The top two product lines—Simparica/Simparica Trio and Apoquel/Apoquel Chewable—contributed approximately 16% and 12% of revenue respectively, and the top five product lines combined contributed roughly 42%. That concentration means headline growth is heavily tied to a small set of franchises.

The profitability figures support the idea that Zoetis operates with pricing power and capital efficiency, but they do not guarantee a permanently wide moat. The 27.5% net margin and 69.3% return on equity are strong, and the global footprint across more than 100 countries provides diversification. Still, with roughly 70% of revenue tied to companion animals, the company is exposed to pet-owner discretionary spending patterns in developed markets.

Zoetis currently carries a market capitalization of $29.9 billion and trades at a P/E ratio of 11.7. That multiple is lower than what many investors historically associated with a high-quality animal-health franchise, which is consistent with the recent headline pressure described below. The 27.5% net margin and 69.3% ROE remain elevated relative to the broader healthcare sector, while the beta of 0.73 indicates lower observed sensitivity to broad equity-market movements.

At a current share price of $71.41, the stock sits below its 50-day exponential moving average of $74.27, with an RSI of 45.8. That technical positioning is neutral rather than stretched, which aligns with a value-style Rubik’s cube rather than a momentum setup.

Zoetis’s most recent SEC 10-K filing describes near-term priorities focused on pipeline development, vaccine readiness and diagnostic integration. The company plans to continue focusing on the discovery and development of new chemical, biopharmaceutical and biological entities, together with product lifecycle innovation for existing franchises. It is also pursuing new vaccines for emerging infectious diseases under what it calls a “first to know and fast to market” operating philosophy.

On the diagnostics side, management is integrating new AI-driven capabilities into the Vetscan Imagyst platform to expand veterinary point-of-care testing. Operationally, 2026 includes a reporting-structure change: Zoetis intends to eliminate the one-month reporting lag for subsidiaries outside the U.S. and align the fiscal years of subsidiaries within the U.S. and International segments.

The portfolio has already been reshaped. On October 31, 2024, Zoetis completed the divestiture of its medicated feed additive product portfolio, certain water soluble products and related assets. Because livestock products represented only about 29% of 2025 revenue, that divestiture further tilts the remaining business toward companion-animal spend.

As a specialty and generic drug manufacturer serving animal health, Zoetis carries industry-level exposures that extend beyond company-specific execution. Regulatory oversight of veterinary pharmaceuticals, vaccines and feed-additive products is a durable factor; changes in registration requirements, withdrawal timelines or environmental rules for livestock medications can alter product economics.

Trade policy and currency fluctuation matter because roughly 45% of revenue comes from outside the U.S. Tariffs on active pharmaceutical ingredients, finished medicines or diagnostic equipment could affect margins or regional demand. Livestock economics are also tied to commodity prices and feed costs, which influence herd sizes and producer willingness to spend on preventive care. Currency translation effects are relevant since International revenue is partly denominated in euros, Chinese yuan, Brazilian reals and other currencies. Supply-chain considerations—such as biotechnology inputs, cold-chain distribution and manufacturing-site concentration—are additional sector-wide risks for this industry.

Recent headlines have reflected a defensive sentiment around the stock. On September 30, 2026, Seeking Alpha published “Zoetis: Priced For The Worst, Worth Buying,” framing the valuation as already discounting negative scenarios. On September 24, 2026, Zacks released “Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note.” The same day, Zoetis announced via Business Wire that it would host a webcast and conference call covering third-quarter 2026 financial results. On October 1, 2026, Zacks followed with “Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why.”

Taken together, these items point to a period of relative underperformance versus the broader market in late September and early October 2026, alongside the countdown to the next quarterly report on November 5, 2026.

Over the last eight reported quarters, Zoetis has beaten earnings estimates seven times, producing an 88% beat rate with an average earnings surprise of 3.9%. By that measure, the company has consistently cleared the market's real expectation. Yet the average 5-day price move following those reports is negative 4.1%, classified as a “down” drift. That disconnect is the central analytical feature for anyone evaluating ZTS around earnings: a beat has not reliably produced a pop and hold.

The last four reports illustrate the pattern directly. On August 6, 2026, Zoetis reported EPS of $1.87 against an estimate of $1.85, a 1.1% positive surprise, yet the stock fell 5.97% the next day and 1.85% over the following five sessions. On May 7, 2026, the company missed by 4.4%, posting actual EPS of $1.53 versus an estimate of $1.60, and the stock dropped 5.13% the next day and 13.55% over the following five days. The February 12, 2026 report was an exception: EPS of $1.48 beat the $1.40 estimate by 5.7%, and the stock rose 0.8% the next day and 2.5% over five days. But the November 4, 2025 report returned to the broader pattern: a 4.9% beat, with actual EPS of $1.70 versus an estimate of $1.62, was followed by a 3.19% decline the next day and a 3.49% decline over five sessions.

Possible explanations include the unofficial consensus running ahead of the published estimate, so the headline beat does not clear the higher bar embedded in the price. Post-earnings selling may also reflect de-risking by holders who had bought into depressed expectations, or concerns about forward guidance tied to companion-animal demand. The 5-day average drift of negative 4.1% is an average, so individual reactions vary, but the overall direction suggests that earnings-day commentary and guidance matter more than the EPS surprise alone.

The next scheduled report is November 5, 2026, before the market open. The current consensus EPS estimate is $1.52.